Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a smartphone app help heart patients recover at home?

NCT ID NCT06816693

Knowledge-focused Sponsor: Chang Gung University of Science and Technology Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a 12-week mobile app program for heart rehab is practical and liked by patients with coronary heart disease. 34 adults used the app after leaving the hospital, and researchers tracked how many signed up, used the app, and stayed in the program. The goal was to see if this approach is worth studying further, not to measure health outcomes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tele-CR program (behavioral intervention via mobile app)
What this could lead to
If successful, this could pave the way for a larger trial testing whether app-based rehab improves heart health outcomes.
What could go wrong
This is a small, early feasibility study with only 34 participants, so results may not apply to all heart patients. It does not measure actual health improvements.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

34 people

The number who actually took part.

Started

Mar 2025

Finished

Jan 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients admitted to the hospital with a primary diagnosis of CHD will be conducted. We plan to recruit a group of patients to receive the tele-CR program and evaluate the usability of the App perceived by patients at 1 and 3 months after discharge. Therefore, we use the t-test (one sample case) statistical method and set the effect size to a moderate 0.5, power is 0.8, alpha is 0.05 (two-tailed), and the number of samples required after calculation using G\*power 3.1 software is 34. Considering the 20% attrition rate, we estimate that we will recruit 45 cases (quantitative). The number of samples for qualitative research is mainly to achieve data saturation, and according to the literature, it is recommended to have at least 12 people.

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. The main diagnosis at admission of CHD. 2. Age ≥20 years. 3. Owns an iOS or Android smartphone and can use it. 4. Conscious, clear and can communicate. 5. Agrees to participate in the research after explanation and is willing to use the App. Exclusion Criteria: 1. Level IV on the New York Heart Association Functional Classification. 2. Left ventricular ejection fraction≦40%. 3. Have a history of severe arrhythmia (e.g., ventricular tachycardia, ventricular fibrillation, complete atrioventricular block). 4. Combined with other serious heart diseases (e.g., congenital heart disease, cardiomyopathy). 5. Mental disorders, end-stage renal disease and other systemic diseases diagnosed by a physician. 6. Severe infection, injury, surgery (e.g., coronary artery bypass graft) or cancer treatment has occurred in the past three months. 7. Physical activities are affected by neurological, respiratory, skeletal, or peripheral vascular diseases. 8. Restricted use of the App due to sensory or cognitive impairment. 9. Already participated in other clinical trials. 10. Planning to receive surgery (e.g., coronary artery bypass graft).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Coronary arterial disease (CAD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder Coronary Disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Coronary arterial disease (CAD) Coronary heart disease

Contacts and locations

Locations

  • Chang Gung Memorial Hospital

    Taoyuan, Guishan Dist., 333, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.